CMS is removing its restrictive national coverage determination (NCD) for positron emission tomography (PET) beta amyloid imaging and will allow Medicare Administrative Contractors (MACs) and Medicare Advantage plans to make determinations on covering the tests, a move that is expected to allow wider access to newer Alzheimer’s disease drug like Leqembi that combat beta amyloid (Aβ) plague.